Mr. Hugh Rogers reports

BIONXT ANNOUNCES CLOSING OF SHARES FOR DEBT SETTLEMENT

Further to the news release dated Jan. 23, 2026, Bionxt Solutions Inc. has issued an aggregate of 6,008,883 common shares in the capital of the company at a deemed price of 45 cents per debt share to settle $2,704,000 in debt owed to certain arm's-length creditors. The debt was composed of a principal amount of $2.6-million and accrued interest of $104,000 pursuant to 8 per cent convertible debentures issued by the company on Dec. 7, 2022.

In connection with the debt settlement, the company issued 300,444 common shares in the capital of the company to Canaccord Genuity Corp. at a deemed price of 63 cents per compensation share as compensation for facilitating the debt settlement.

Each of the debt shares and the compensation shares is subject to a statutory four-month-and-one-day hold period in accordance with applicable Canadian securities laws.

About Bionxt Solutions Inc.

Bionxt is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity. With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange and the OTCQB Markets and trades in Germany under WKN: A3D1K3.